Forex losses and US import ban hit Ranbaxy in fourth quarter
This article was originally published in Scrip
Ranbaxy Laboratorieshas reported a loss of Rs6.79 billion ($142 million) for the fourth quarter ended December 31st, dented by foreign exchange losses, adoption of an accounting standard aimed at improved transparency and the ongoing US import alert on its products for alleged good manufacturing practice (GMP) violations.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.
Glenmark and Sun Pharma introduce nintedanib generics in India at a fraction of the innovator product’s price, vying for a share of the IPF market where pirfenidone currently holds sway.